HLA
GBT

Hamilton Lane Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Hamilton Lane Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,248
Closed -$600K – 56
2017
Q4 		$600K Buy
+15,248
New +$569K 0.31% 44
2017
Q3 		– Sell
-108,786
Closed -$2.98M – 64
2017
Q2 		$2.98M Buy
+108,786
New +$3.24M 1.63% 16
2017
Q1 		– Sell
-14,628
Closed -$211K – 73
2016
Q4 		$211K Buy
+14,628
New +$257K 0.14% 58

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Hamilton Lane Advisors's GBT Position: Q1 2018 in Review

Hamilton Lane Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2018, closing a stake of 15,248 shares — an estimated $600K sold.

Hamilton Lane Advisors first reported a position in GBT in Q4 2016 and held it in 3 quarters. The position peaked at $2.98M in Q2 2017. 176 funds tracked by Wall St. Rank hold GBT as of Q1 2018.

  • Hamilton Lane Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Hamilton Lane Advisors sold 15,248 Global Blood Therapeutics, Inc. shares in Q1 2018, an estimated $600K.
  • Hamilton Lane Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2016 and held it in 3 quarters.
  • Hamilton Lane Advisors's Global Blood Therapeutics, Inc. position peaked at $2.98M in Q2 2017.
  • 176 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2018.

Based on Hamilton Lane Advisors's 13F filing for Q1 2018, filed 3 May 2018.